The article discusses the role of chronic inflammation in cancer development and the potential for therapeutic intervention to neutralize this inflammation. It highlights the complex interplay between immune cells and cancer, emphasizing the plasticity of immune cells and their ability to exert both pro- and antitumor effects. The authors review clinical and experimental studies that identify specific immune cell subsets, such as T helper (TH) cells and myeloid cells, which can promote tumor growth through various mechanisms, including the secretion of cytokines, chemokines, and proteolytic enzymes. They also discuss the therapeutic strategies that target these immune cells, including selective inhibition of cytokines, depletion or reprogramming of tumor-associated immune cells, and harnessing cytotoxic T cells. The article concludes by emphasizing the importance of integrating immunometrics into traditional classification schemes and the need for personalized medicine to effectively manage cancer.The article discusses the role of chronic inflammation in cancer development and the potential for therapeutic intervention to neutralize this inflammation. It highlights the complex interplay between immune cells and cancer, emphasizing the plasticity of immune cells and their ability to exert both pro- and antitumor effects. The authors review clinical and experimental studies that identify specific immune cell subsets, such as T helper (TH) cells and myeloid cells, which can promote tumor growth through various mechanisms, including the secretion of cytokines, chemokines, and proteolytic enzymes. They also discuss the therapeutic strategies that target these immune cells, including selective inhibition of cytokines, depletion or reprogramming of tumor-associated immune cells, and harnessing cytotoxic T cells. The article concludes by emphasizing the importance of integrating immunometrics into traditional classification schemes and the need for personalized medicine to effectively manage cancer.